Type 2 diabetes (T2D) affects 422 million adults worldwide. The number of individuals affected by T2D in the future is expected to rise, as several factors which confer risk for T2D are also increasing, including over- and undernutrition, declining physical activity, increased stress, and presence of adverse socioeconomic and environmental factors. This health crisis is occurring simultaneously to another looming health epidemic, namely an increase in the incidence of dementia, especially the Alzheimer clinical syndrome.

Considerable evidence indicates that type 2 diabetes (T2D) and related features such as insulin resistance are associated with increased risk for dementia. Consequently, there has also been a great deal of interest in determining to what extent antidiabetic treatments may either protect against dementia or be used as treatments for cognitive dysfunction. This review will provide a brief overview of studies that link T2D with dementia, in particular Alzheimer disease (AD), the state of evidence linking antidiabetic treatments with either protection against dementia or possibly increased risk for cognitive dysfunction, and provide a brief overview of what has been learned from clinical trials testing antidiabetic treatments in Alzheimer disease.

Keywords: Alzheimer disease; APOE ε4; biomarker; clinical trial; dementia; m etform in; risk; type 2 diabetes

Introduction

Type 2 diabetes (T2D) affects 422 million adults worldwide. The number of individuals affected by T2D in the future is expected to rise, as several factors which confer risk for T2D are also increasing, including over- and undernutrition, declining physical activity, increased stress, and presence of adverse socioeconomic and environmental factors. This health crisis is occurring simultaneously to another looming health epidemic, namely an increase in the incidence of dementia, especially the Alzheimer clinical syndrome.

In addition to the well-known risk factors for AD, including age, apolipoprotein (APOE) ε4 genotype, and parental history of AD, there has been a long-standing interest in determining the risk conferred by vascular risk factors, and
Original article
Antidiabetic therapies and Alzheimer disease - Bendlin

especially T2D. Population-based studies largely support an association between T2D and elevated dementia risk. The Rotterdam study was among the first to show an elevated risk of dementia with T2D, including vascular dementia and AD. Both the Hisayama study in Japan and the Vantaa 85+ study in Finland found a doubling of dementia risk with T2D. Among participants in the Religious Orders Study, T2D was associated with a 65% increase in the risk of developing AD compared with those without T2D. The Kungsholmen Project, a longitudinal population-based study based in Stockholm, found that T2D as well as pre-diabetes accelerated the progression from mild cognitive impairment (MCI) to dementia by 3.18 years. The Cache county study also found an increased risk of dementia among individuals with T2D, although the effect was restricted to women. Similarly, the Framingham study found that the risk for dementia conferred by T2D may be restricted to subgroups, including younger participants (<75 years of age), and individuals who do not carry the AD risk gene APOE ε4 genotype. The increased association between T2D and dementia appears to be stronger when T2D is present in midlife rather than older age, with some suggestion that diabetes-related abnormalities occurring as early as young adulthood may impact later cognitive function.

Type 2 diabetes and the pathology of Alzheimer disease

There are several potential mechanisms by which T2D may impact risk for dementia. Vascular mechanisms are likely, given the well-known adverse effects of T2D on vascular health; T2D is associated with cardiovascular disease, lower cerebral perfusion, small-vessel disease, and stroke. T2D-associated abnormalities in insulin are also plausible contributors to dementia risk. Peripheral insulin resistance has been associated with several brain differences, including lower cerebral glucose uptake, reduced cerebral perfusion, and atrophy. In addition to the peripheral insulin abnormalities that are present in T2D, central insulin resistance—characterized by downregulation of insulin receptors, lowered binding of insulin, and abnormal insulin signaling—is also a feature of the AD brain.

Despite the mixed findings of observational studies, a large body of literature and several compelling hypotheses still suggest that antidiabetic therapies hold potential as treatments for dementia

As covered elsewhere in this issue, AD is defined by the presence of β-amyloid plaques, neurofibrillary tangles, and ultimately, neurodegeneration. However, the extent to which T2D can be directly related to the cardinal features of AD is unclear, particularly in human studies. Animal studies are supportive of a link, demonstrating that T2D can exacerbate AD pathology, including development of amyloid plaques, tau pathology, and neurodegeneration. Some human evidence also points toward a link between T2D and AD pathology; Matsuzaki et al examined lab and autopsy information for 135 individuals and found that antemortem plasma glucose, fasting insulin, and the homeostatic model assessment of insulin resistance (HOMA-IR) were associated with increased risk for amyloid plaques post mortem, especially among individuals with APOE ε4 genotype.

More often, however, human studies examining the link between T2D and AD pathology have been negative, particularly with regard to amyloid. Heitner et al compared 49 diabetics to 52 age-matched controls and did not find elevated AD pathology. In a larger study of 1037 subjects examined at autopsy, T2D (n=279) was not associated with plaque and tangle burden, although APOE ε4 moderated the association such that carriers had higher odds of accumulating tangles. Alafuzoff et al examined 701 brains, where 134 were from individuals who were diabetic, and did not find an association between T2D and AD pathology. Similarly, in vivo studies using positron emission tomography (PET) or CSF analysis suggest that T2D is not associated with greater amyloid accumulation, although Moran et al found a relationship between T2D and higher tau pathology as measured in CSF.

One possibility that has been advanced is that antidiabetic treatment among individuals with T2D could mitigate AD pathology. Beeri et al examined brain autopsy data derived from 248 subjects, half with T2D and half non-T2D...
Examining medication usage specifically, individuals with a history of combined use of insulin and oral antidiabetic medications (n=18) had significantly fewer amyloid plaques in all brain regions assessed, suggesting a possible beneficial effect of therapy on AD pathology.

Thambisetty et al are among the few who—like Beeri et al—also examined medication usage in relation to AD pathology as assessed with PET or postmortem assessment of AD pathology. They found that T2D was not associated with AD pathology, and that among the subset taking antidiabetic medications, there was no difference in level of AD pathology. Unlike the study by Beeri et al, however, combination therapy was not examined and the number of individuals who were taking insulin was small. A couple of studies have also found that individuals with T2D have lower AD pathology compared to controls. Ahtiluoto et al found that the proportion of individuals with β-amyloid plaques measured on autopsy was significantly lower among diabetic compared to nondiabetic individuals.

Likewise, Nelson et al observed significantly lower neurofibrillary counts in the subiculum and lower amyloid plaque count in temporal lobe among diabetics compared with non diabetics. However, these latter two studies did not examine the impact of medication specifically, and in light of the largely mixed literature on the relationship between T2D and AD pathology, it is almost impossible to draw conclusions on the impact of medications from observational studies alone.

Medications for type 2 diabetes and risk for dementia

Determining whether antidiabetic medications mitigate risk for dementia is complicated. Among individuals with T2D, observational studies are confounded by the fact that the effect of antidiabetic medication is not easily separated from the presence of T2D. Furthermore, there are multiple approaches to treating T2D. In addition to recommendations pertaining to diet, physical activity, and other lifestyle factors, treatment of T2D may involve several drug classes, including metformin, sulfonylureas, thiazolidinediones (TZDs), sodium-glucose cotransporter 2 (SGLT2) inhibitors, alpha-glucosidase inhibitors, glucagon-like peptide 1 (GLP1)-based therapies (GLP-1 agonists and dipeptidyl peptidase-4 inhibitors), and insulin. Only a subset of these have been examined in relation to dementia in observational studies (as either monotherapy, or as part of combination therapies), and even fewer have been tested in human clinical trials for AD.

Metformin is typically the first medication prescribed for T2D, reducing the production of glucose in the liver, increasing uptake of glucose by the periphery, and improving insulin sensitivity. In a study of records from individuals 50 years of age or older in Taiwan’s National Health Insurance database, where n=25,393 had a diagnosis of T2D and n=101,816 did not have a diagnosis of T2D, Hsu et al found that dementia was increased 2.6-fold among individuals with T2D. Encouragingly, use of metformin reduced the risk of dementia by 24% compared with no use of antidiabetic medication. Sulfonylureas—which trigger release of endogenous insulin by binding to and closing ATP-sensitive K+ channels on the cell membrane of pancreatic β-cells—reduced dementia risk by 15%. When used in a combined regimen, these two oral antidiabetic agents decreased the risk of dementia in patients with T2D by 35% over 8 years. Adjusting for cerebrovascular disease did not change the association, suggesting that the reduced risk may occur independently from vascular mechanisms.

Heneka et al examined the association between pioglitazone and incidence of dementia utilizing data from a mandatory German public health insurance company. Data included longitudinal observations from 145,928 subjects who were 60 years of age or older and free of dementia and insulin-dependent diabetes at baseline. Subjects were either nondiabetics, diabetics who did not use pioglitazone, diabetics treated with pioglitazone for shorter periods (less than 8 calendar quarters of use), or diabetics treated for longer periods (eight or more quarters of pioglitazone use). Controlling for age, sex, use of rosiglitazone or metformin, and cardiovascular comorbidities, a diagnosis of diabetes without pioglitazone treatment was associated with a 23% increased risk for dementia. In turn, long-term use of pioglitazone was associated with a lower dementia incidence, while shorter-term pioglitazone use was associated with a dementia risk comparable to that of nondiabetics.

Utilizing data from the Sacramento Area Latino Study on Aging (SALSA Study), Wu et al examined the longitudinal association between antidiabetic medications and physical and cognitive functioning among older
Antidiabetic therapies and Alzheimer disease - Bendlin

community-dwelling Mexican Americans. Antidiabetic drugs included insulin in addition to oral glucose-lowering agents comprising metformin, sulfonylureas, thiazolidinediones, alpha-glucosidase inhibitors, and meglitinides. Among 1789 study participants, 585 (32.7%) were identified as having T2D at baseline. There was a positive effect of antidiabetic medication on both physical and cognitive function, with combination therapy of two or more antidiabetic agents resulting in a lower risk than monotherapy.

However, associations between antidiabetic medication and dementia are not uniformly in the direction of increased protection. A case-control study of 14 172 participants aged 65 years and older found that metformin was associated with an increased risk of AD dementia. In the Rotterdam Study, risk of incident dementia was highest among patients treated with insulin. Likewise, a Taiwanese study found that combination therapy with insulin was associated with greater risk of AD. It is possible in these studies that T2D or the severity of T2D—not medication—conferred the increased risk, although controlling for time since diagnosis (which was done in Huang et al) may approximate disease severity.

Antidiabetic medication as an intervention for dementia

Despite the mixed findings of observational studies, a large body of literature and several compelling hypotheses still suggest that antidiabetic therapies hold potential as treatments for dementia. Of particular interest, are observations that T2D and AD appear to share mechanisms in common, including abnormalities in insulin signaling, mitochondrial dysfunction, abnormal energy homeostasis, and neuroinflammation.

Antidiabetic medications have examined the extent to which antidiabetic medications may impact brain pathology—particularly features of AD—with the majority of animal studies pointing toward potential benefits on amyloid pathology, tau pathology, synapses, oxidative stress, neurogenesis, and cognitive function.

However, human clinical trials—such as observational studies—show mixed findings. Promising effects of antidiabetic medications have been observed in relatively smaller trials. In a promising small trial, Luchsinger et al tested the effects of metformin among 80 participants with amnestic MCI and no diagnosis of T2D and found a beneficial effect of m etformin on verbal memory. A small placebo-controlled crossover study randomized twenty nondiabetic participants with MCI or mild AD dementia to metformin followed by placebo or vice versa for 8 weeks and found a significant positive effect of m etformin on executive function, specifically Trials B. In addition to m etformin, sm all trials of TZDs have also shown beneficial effects. A small pilot study which randomized patients with AD/amnestic MCI to oral rosiglitazone or placebo for 6 months found better delayed recall at both 4 and 6 months, as well as better selective attention at 6 months. Pioglitazone was tested among 42 individuals with mild AD and an accompanying diagnosis of T2D and found a benefit of pioglitazone compared with control on MMSE and the Japanese version of ADAS-Cog scores. However, a caveat was the open-label study design.

Larger trials have been routinely negative. An efficacy and tolerability study of rosiglitazone randomized 518 patients with mild-to-moderate AD to various doses of rosiglitazone (2, 4, or 8 mg) or placebo. No effects were observed at 24 weeks on the primary end points including change from baseline in ADAS-Cog or the Clinician’s Interview-Based Impression of Change Plus Caregiver Input. In a follow-up phase 3 study with the same outcomes, 693 participants were stratified by APOE genotype. Again, no significant effects of rosiglitazone were observed in either the overall sample or within APOE4 subgroups at week 24.

In the largest trial of its kind to date, a global, phase 3, multicenter, double-blind, randomized, placebo-controlled clinical trial evaluated the efficacy of low-dose pioglitazone as a treatment to delay onset of MCI in cognitively unimpaired individuals who were identified as high risk by a genetic risk algorithm. The study—which involved 50 clinical sites and screening of 25 000 people—enrolled 3494 cognitively unimpaired participants who were screened on APOE and TOMM40 genotype. The trial ended early following an interim futility analysis, which showed an inadequate treatment effect of 0.8 mg of sustained release pioglitazone in delaying the onset of MCI due to AD.
Given observed abnormalities in insulin receptor density and insulin signaling in AD, a novel approach to therapy tested in several small and larger trials involves intranasal delivery of insulin. Intranasal delivery tempers the risks that would be involved if insulin were delivered peripherally, including insulin resistance and hypoglycemia. Early results from intranasal insulin trials were promising. For example, an early pilot trial tested a 3-week intervention comparing intranasal insulin with placebo in 24 individuals with amnestic MCI or mild AD and found positive impacts on verbal memory and attention. In a separate trial that examined differing doses of intranasal insulin among 33 people with amnestic MCI/early AD and 59 cognitively unimpaired adults, beneficial effects were observed on verbal memory specifically among those receiving insulin as monotherapy.

APOE ε4 non-carriers. In contrast, m emory-im paired APOE ε4 carriers showed a decline in verbal memory in response to intranasal insulin.66 In 2013, the multi-site Study of Nasal Insulin in the Fight against Forgetfulness (SNIFF) trial was launched. Participants with amnestic MCI or AD (n=289) were enrolled at 26 sites. Recently presented results of the primary analysis of data from 24 individuals who utilized a newly available nasal delivery device indicated no impact of intranasal insulin on the primary cognitive outcome.67 The results of additional analyses (for example, analyses by APOE ε4 genotype) are still pending, and it is important to note that a mid-study change in delivery device, which occurred due to malfunction of the original device, may have also impacted the outcome.

Tight control of T2D is not associated with cognitive benefit. The ACCORD study did not support a beneficial effect of intensive glycemic treatment (HbA1c <6%) on cognitive function, either at the time the intensive treatment arm was stopped due to mortality risks or 47 months later.68 Furthermore, tight glycemic control could increase the occurrence of hypoglycemia, which in turn may contribute to cognitive impairment.

Only a small number of trials have examined the impact of antidiabetic medications on potential markers of AD pathology. The effect of metformin on CSF biomarkers of AD was evaluated in a small trial (n=20), but results did not show any effect.57 In a small trial carried out by the Craft group testing the impact of rosiglitazone on cognitive function, plasma Aβ42 levels did not change in the group receiving rosiglitazone (n=20), but showed a decline among individuals in the placebo group.56 In a small study from Sato et al which tested pioglitazone, plasma Aβ40/ Aβ42 remained stable in the treated group but increased in the control group. The import of these findings is unclear given the small Ns and limited validation of plasma amyloid assays as markers of CNS amyloid. Markers of amyloid and tau pathology have also been evaluated in cerebrospinal fluid as part of single center and larger multisite trials of intranasal insulin. Insulin has been found to lower ptau/Aβ42 in at least one study,71 although another single site study from this same group did not show an effect, and early results from SNIFF did not suggest an effect on CSF biomarkers.

Considerations for the future

Given the evidence that links T2D with dementia risk, pathophysiological similarities between T2D and AD, as well as promising small trials, why are medications targeting these mechanisms ineffective in larger trials?

An issue that has plagued prior trials concerns the timing of interventions in relation to disease course: are treatments initiated when a disease process is already substantially underway and thus less effective? Among individuals with AD, and even MCI, by definition there is usually substantial plaque and tangle burden apparent, as well as neurodegeneration. With regard to testing medications which act on insulin, the issue of timing may also extend beyond cognitive severity or degree of amyloid and tau pathology. For example, activity of the enzymes phosphodiesterase, glycogen synthase kinase 3β, and insulin degrading enzyme, are altered in T2D as well as AD, linking the two diseases, but abnormalities may occur upstream of the development of AD pathology, such that interventions may need to be initiated earlier to be effective. Furthermore, consider the example of hormone therapy as tested in the Women’s Health Initiative study. After risks of hormone therapy such as coronary heart disease, breast cancer, and cognitive decline were discovered, the suggestion was offered that initiating hormone therapy several years postmenopause onset was a poor strategy. Therapies targeting the hormone insulin may need to be equally sensitive to timing issues, as age and disease associated changes to insulin receptors evolve and may differ among individuals.

Are trials enrolling participants who are most likely to benefit? For example, in the case of treatments tested as...
antidiabetic therapies and Alzheimer disease - Bendlin

interventions for AD, do the participants harbor AD pathology, or is it a heterogeneous group with various pathologies? Given the unique targets of T2D medications, it may be further necessary to refine the selection of participants to those with metabolic abnormalities. For example, while a phase 3 trial of azeliragon—which inhibits the receptor for advanced glycation end products—was terminated after it was found that patients with mild AD taking azeliragon did not improve on cognition or functional outcomes compared with placebo,74 a subgroup of AD patients with diabetes and high HbA1c did appear to benefit.75 Likewise, insulin sensitizers may need to be selectively tested among individuals who have confirmed central (or possibly peripheral) insulin resistance. Genotype will also play a role, as has become clear with multiple studies of T2D, insulin resistance, and trials of antidiabetic medications; in particular, there is substantial accumulating data pointing toward APOE4 as a critical variable in studies relating to energy metabolism and metabolic dysregulation. Unfortunately, despite the many studies suggesting its importance, how it should be handled in clinical trials is not precisely clear. In at least one study, it appears that carriers benefit from treatment,6 while in other cases, the evidence suggests noncarriers benefit.61,77 Similar inconsistencies are apparent with regard to T2D and AD, or the impact of T2D medications. A number of issues confound the interpretation of observational studies, including the co-occurrence of T2D, treatment for T2D, and comorbidities. A major gap at present for testing antidiabetic therapies in AD is that the mechanisms which tie T2D to the Alzheimer clinical syndrome are not entirely known and may not be via AD-specific pathology, or they may be upstream phenomena, preceding pathology. Mitigating instigators of pathology may require treating individuals early, prior to development of extensive amyloid and tau tangle burden for maximum effectiveness.

It may also be the case that T2D therapies, while having beneficial effects on certain aspects of disease, may exacerbate other disease features if unopposed. Human, rodent, and cell model studies cumulatively suggest that combination therapy could be preferable to monotherapy.37,41,84,85

Other factors that are difficult to parse are whether the impact of T2D directly impacts the brain through an insulin-mediated mechanism, or whether risks for dementia are due to accompanying factors such as obesity, dyslipidemia, hypertension, or the impact of advanced glycation end-products, all of which may have independent or synergistic impacts on the brain. A beneficial approach may be to consider treatment of T2D as part of a broader strategy to control vascular risk factors to attenuate cognitive decline.86

Conclusion

Despite several epidemiologic studies, animal studies, and small trials, there are no gold-standard studies that have unequivocally sealed the case between T2D and AD, or the impact of T2D medications. A number of issues confound the interpretation of observational studies, including the co-occurrence of T2D, treatment for T2D, and comorbidities. A major gap at present for testing antidiabetic therapies in AD is that the mechanisms which tie T2D to the Alzheimer clinical syndrome are not entirely known and may not be via AD-specific pathology, or they may be upstream phenomena, preceding pathology. Mitigating instigators of pathology may require treating individuals early, prior to development of extensive amyloid and tau tangle burden for maximum effectiveness.

Strategies for optimizing treatment trials are still needed, including improved patient selection, determining the correct timing of treatment in relation to disease course, and identification of suitable biomarkers for evaluating therapies that currently have multifactorial or perhaps even unknown mechanisms of action. Indeed, a major advancement in the field of AD clinical trials has been the improved precision by which individuals with disease pathology can be identified, especially prior to developing cognitive dysfunction. As the field moves toward ever better biomarkers of disease processes, testing and developing drugs related to the specific processes that connect T2D with AD remain a viable area of inquiry and development.

Disclosure/Acknowledgements: The author has no conflicts of interest to disclose. The author receives support from the National Institute on Aging.
Original article
Antidiabetic therapies and Alzheimer disease - Bendlin

References

1. WHO. Global report on diabetes. World Health Organization; 2016.
2. Kong AP, Xu G, Brown N, So WY, Ma RC, Chan JC. Diabetes and its comorbidities—where East meets West. Nat Rev Endocrinol. 2015;9(9):537-547.
3. DeFronzo RA, Ferrannini E, Groop L, et al. Type 2 diabetes mellitus. Nat Rev Dis Primers. 2015;1:15019.
4. Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM. Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology. 1999;53(9):1937-1942.
5. Ott A, Stolk RP, Hofman A, van Harskamp F, Grobbee DE, Breteler MM. Association of diabetes mellitus and dementia: the Rotterdam Study. Diabetologia. 1996;39(11):1392-1397.
6. Ohara T, Doi Y, Ninnomyia T, et al. Glucose tolerance status and risk of dementia in the community: the Hisayama study. Neurology. 2011;77(12):1126-1134.
7. Ahlituoto S, Polvikoski T, Peltonen M, et al. Diabetes, Alzheimer disease, and vascular dementia: a population-based neuropathologic study. Neurology. 2010;75(13):1195-1202.
8. Arvanitakis Z, Wilson RS, Bienias JL, Evans DA, Bennett DA. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol. 2004;61(5):661-666.
9. Xu W, Caracciolo B, Wang HX, et al. Accelerated progression from mild cognitive impairment to dementia in people with diabetes. Diabetes. 2010;59(11):2928-2935.
10. Hayden KM, Zandi PP, Lyketsos CG, et al. Vascular risk factors for incident Alzheimer disease and vascular dementia: the Cache County study. Alzheimer Dis Assoc Disord. 2006;20(2):93-100.
11. Akomolafe A, Reiser A, Meigs JB, et al. Diabetes mellitus and risk of developing Alzheimer disease: results from the Framingham Study. Arch Neurol. 2006;63(11):1551-1555.
12. Xu W, Qiu C, Gatz M, Pedersen NL, Johansson B, Fratiglioni L. Mid- and late-life diabetes in relation to the risk of dementia: a population-based study. Diabetes. 2009;58(1):71-77.
13. Schneider Beeri M, Goldbourt U, Silverman JM, et al. Diabetes mellitus in midlife and the risk of dementia three decades later. Neurology. 2004;63(10):1902-1907.
14. Bancks MP, Carneith MR, Jacobs DR, Jr., et al. Fasting glucose variability in young adulthood and cognitive function in middle age: The Coronary Artery Risk Development in Young Adults (CARDIA) Study. Diabetes Care. 2018.
15. Shah AD, Langenberg C, Rapsomaniki E, et al. Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1.9 million people. Lancet Diabetes Endocrinol. 2015;3(2):105-113.
16. Dai W, Duan W, Alfaro FJ, Gavielli A, Kourtelidis F, Novak V. The resting perfusion pattern associates with functional decline in type 2 diabetes. Neurobiol Aging. 2017;60:192-202.
17. Manschot SM, Biessels GJ, de Valk H, et al. Metabolic and vascular determinants of impaired cognitive performance and abnormalities on brain magnetic resonance imaging in patients with type 2 diabetes. Diabetologia. 2007;50(11):2388-2397.
18. Nelson PT, Smith CD, Abner EA, et al. Human cerebral neuropathology of Type 2 diabetes mellitus. Biochim Biophys Acta. 2009;1792(5):454-469.
19. Larsson SC, Scott RA, Traylor M, et al. Type 2 diabetes, glucose, insulin, BMI, and ischemic stroke subtypes: Mendelian randomization study. Neurology. 2017;89(5):454-460.
20. Baker LD, Cross DJ, Minoshima S, Longia D, Watson GS, Craft S. Insulin resistance and Alzheimer-like reductions in regional cerebroglucose metabolism for cognitively normal adults with prediabetes or early type 2 diabetes. Arch Neurol. 2011;68(1):51-57.
21. Hoscheidt SM, Kellawan JM, Berman SE, et al. Insulin resistance is associated with lower arterial blood flow and reduced cortical perfusion in cognitively asymptomatic middle-aged adults. J Cereb Blood Flow Metab. 2017;37(6):2249-2261.
22. Willette AA, Xu G, Johnson SC, et al. Insulin resistance, brain atrophy, and cognitive performance in late-middle-aged adults. Diabetes Care. 2013;36(2):443-449.
23. Talbot K, Wang HY, Kazi H, et al. Demonstrated brain insulin resistance in Alzheimer’s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest. 2012;122(4):1316-1338.
24. Frolich L, Blum-Degen D, Bernstein HG, et al. Brain insulin and insulin receptors in aging and sporadic Alzheimer’s disease. J Neural Transm (Vienna). 1998;105(4-5):423-438.
25. Bom fmi TR, Forny-Germ ano L, Sather LB, et al. An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer’s disease- associated Abeta oligomers. J Clin Invest. 2012;122(12):1339-1353.
26. Arnold SE, Arvanitakis Z, Macauley-Rambach SL, et al. Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums. Nat Rev Neurol. 2018;14(3):168-181.
27. Jack CR, Jr., Bennett DA, Blennow K, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018;14(4):535-562.
28. Ramos-Rodriguez JJ, Spires-Jones T, Poorer AM, Lechuga-Sancho AM, Bacsak BJ, Garcia-Alloza M. Progressive neuronal pathology and synaptic loss induced by prediabetes and type 2 diabetes in a mouse model of Alzheimer’s disease. Mol Neurobiol. 2017;54(5):3428-3438.
29. Wijesekara N, Ahrens R, Sabale M, et al. Amyloid-beta and islet amyloid pathologies link Alzheimer’s disease and type 2 diabetes in a transgenic model. FASEB J. 2017;31(12):5409-5418.
30. Platt TL, Beckett TL, Kohler K, Niedowicz DM, Murphy MP. Obesity, diabetes, and leptin resistance promote tau pathology in a mouse model of disease. Neuroscience. 2016;315:162-174.
31. Matsuzaki T, Sasaki K, Tanizaki Y, et al. Insulin resistance is associated with the pathology of Alzheimer disease: the Hisayama study. Neurology. 2010;75(9):764-770.
32. Heitner J, Dickson D. Diabetics do not have increased Alzheimer-type pathology compared with age-matched control subjects. A retrospective postmortem immunocytochemical and histofluorescent study. Neurology. 1997;49(5):1306-1311.
33. Alafuzoff I, Aho L, Helisalmi S, Mannermaa A, Soininen H. Beta-amyloid deposition in brains of subjects with diabetes. Neuropathol Appl Neurophysiol. 2009;35(1):60-68.
34. Roberts RO, Knopman DS, Cha RH, et al. Diabetes and elevated hemoglobin A1c levels are associated with brain hypometabolism but not amyloid accumulation. J Nucl Med. 2014;55(5):759-764.
35. Moran C, Beare R, Phan TG, et al. Type 2 diabetes mellitus and biomarkers of neurodegeneration. Neurology. 2015;85(13):1123-1130.
36. Tomita N, Furukawa K, Okamura N, et al. Brain accumulation of amyloid beta protein visualized by positron emission tomography and BF-227 in Alzheimer’s disease patients with or without diabetes mellitus. Geriatr Gerontol Int. 2013;13(1):215-221.
37. Beeri MS, Schneider J, Silverman JM, et al. Insulin in combination with other diabetes medication is associated with less Alzheimer neuropathology. Neurology. 2008;71(10):750-757.
38. Thambisetty M, Jeffrey Metter E, Yang A, et al. Glucose intolerance, insulin resistance, and pathological features of Alzheimer disease in the Baltimore Longitudinal Study of Aging. JAMA Neurol. 2013;70(9):1167-1172.
39. Hsu CC, Wahlgvist ML, Lee MS, Tsai HN. Incidence of dementia is increased in type 2 diabetes and reduced by the use of sulfonylureas and metformin. J Alzheimers Dis. 2011;24(3):483-493.
40. Heneka MT, Fink A, Dobhlammer G. Effect of pioglitazone medication on the incidence of dementia. Ann Neurol. 2015;78(2):284-294.
41. Wu JH, Haan MN, Liang J, Ghosh D, Gon-
Antidiabetic therapies and Alzheimer disease - Benldin

1. Impact of antidiabetic medications on physical and cognitive functioning of older Mexican Americans with diabetes mellitus: a population-based cohort study. *Ann Epidemiol.* 2003;13(5):369-376.

2. Infeld P, Bodmer M, Jick SS, Meier CR. Metformin, other antidiabetic drugs, and risk of Alzheimer’s disease: a population-based case-control study. *J Am Geriatr Soc.* 2012;60(5):916-921.

3. Huang CC, Chung CM, Lee HB, et al. Diabetes mellitus and the risk of Alzheimer’s disease: a nationwide population-based study. *PLoS One.* 2014;9(1):e87095.

4. Sims-Thomas C, Kim B, Rosko A, Feldman EL. How does diabetes accelerate Alzheimer disease pathology? *Nat Rev Neurol.* 2010;6(10):551-559.

5. Infante-Garcia C, Ramos-Rodriguez JJ, Hierro-Bujalance C, et al. Antidiabetic polypill improves central pathology and cognitive impairment in a mixed model of Alzheimer’s disease and type 2 diabetes. *Mol Neurobiol.* 2018;55(7):6130-6144.

6. Ou Z, Kong X, Sun X, et al. Metformin treatment prevents amyloid plaque deposition and memory impairment in APP/PS1 mice. *Brain Behav Immun.* 2018;69:351-363.

7. Ma DL, Chen FX, Xu WJ, Yue WZ, Yuan G, Yang Y. Early intervention with glucagon-like peptide 1 analog liraglutide prevents tau hyperphosphorylation in diabetic db/db mice. *J Neurochem.* 2015;135(2):301-308.

8. Kickstein E, Krauss S, Thornhill P, et al. Biguanide metformin acts on tau phosphorylation via nTOR-protein phosphatase 2A (PP2A) signaling. *Proc Natl Acad Sci U S A.* 2010;107(50):21830-21835.

9. Pathak NM, Pathak V, Gault VA, McClean S, Irwin N, Flatt PR. Novel dual incretin agonist peptide with antidiabetic and neuroprotective potential. *Biochem Pharmacol.* 2018;155:264-274.

10. McClean PL, Holscher C, Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer’s disease. *Neuropsychopharmacology.* 2014;86:241-258.

11. Holscher C. The incretin hormones glucagon-like peptide 1 and glucose-dependent insulino trope polypeptide are neuroprotective in mouse models of Alzheimer’s disease. *Alzheimers Dement.* 2014;10(1 Suppl):S47-54.

12. Wang J, Gallagher D, DeVito LM, et al. Metformin activates an atypical PKC-CBP pathway to promote neurogenesis and enhance spatial memory formation. *Cell Stem Cell.* 2012;11(3):23-35.

13. Heneka MT, Sastre M, Dumitrescu-Ozimek L, et al. Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APP/VT7171 transgenic mice. *Brain.* 2005;128(P 6):1442-1453.

14. Batista AF, Forny-Germano L, Clarke JR, et al. The diabetes drug pioglitazone reverses cognitive impairment in mice and attenuates insulin receptor and synaptic pathology in a non-human primate model of Alzheimer’s disease. *J Pathol.* 2018;245(1):85-100.

15. Fernandez-Martos CM, Atkinson RAK, Chuaah MI, King AE, Vickers JC. Combination treatment with leptin and pioglitazone in a mouse model of Alzheimer’s disease. *Alzheimers Dement (N Y).* 2017;3(1):92-106.

16. Luchsinger JA, Perez T, Chang H, et al. Metformin in amnestic mild cognitive impairment: results of a pilot randomized placebo controlled clinical trial. *J Alzheimers Dis.* 2016;52(1):501-514.

17. Koenig AM, Mechanic-Hamilton D, Xu SX, et al. Effects of the insulin sensitizer metformin in Alzheimer disease: pilot data from a randomized placebo-controlled crossover study. *Alzheimer Dis Assoc Dispord.* 2017;31(2):107-113.

18. Watson GS, Choleron BA, Reger MA, et al. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with risgolitazone: a preliminary study. *Am J Geriatr Psychiatry.* 2005;13(11):950-958.

19. Sato T, Hanyu H, Hirao K, Kanetaka H, Sakurai H, Iwamoto T. Efficacy of PPAR-gamma agonist pioglitazone in mild Alzheimer disease. *Neurobiol Aging.* 2011;32(9):1626-1633.

20. Risner ME, Saunders AM, Altman JF, et al. Efficacy of risgolitazone in a genetically defined population with mild to moderate Alzheimer’s disease. *Pharmacogenomics J.* 2006;6(4):246-254.

21. Gold M, Alderton C, Zvartau-Hind M, et al. Rosiglitazone monotherapy in mild-to-moderate Alzheimer’s disease: results from a randomized, double-blind, placebo-controlled phase III study. *Dement Geriatr Cogn Disord.* 2010;30(2):131-146.

22. Budur K, Welsh-Bohmer K, Burns D, et al. A pharmacogenetics-supported clinical trial to delay onset of mild cognitive impairment due to Alzheimer’s disease using low-dose pioglitazone: an update on the tomorrow study. *Alzheimer’s Dement.* 2014;10(4):809-810.

23. Bowman Rogers M. There’s No Tomorrow for TOMMORROW. Available at: https://www.alzforum.org/news/research-news/theres-no-tomorrow-tommorrow. Accessed December 2018.

24. Takeda and Zinfandel Pharmaceuticals Discontinue TOMMORROW Trial Following Planned Futility Analysis [Press release]. Available at: https://www.takeda.com/newsroom/newsreleases/2018/takeda-tommorrow-trial. Accessed December 2018.

25. Reger MA, Watson GS, Green PS, et al. Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults. *J Alzheimers Dis.* 2008;13(3):323-331.

26. CTAD 2018 – Highlights, October 25 [press release]. Available at: http://www.ctad-alzheimer.com/files/files/CTAD%202018%20-%E2%80%93%20Highlights%20October%2025_0.pdf. Accessed December 2018.

27. Launer LJ, Miller ME, Williamson JD, et al. Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. *Lancet Neurol.* 2011;10(11):969-977.

28. Yaffe K, Falvey CM, Hamilton N, et al. Association between hypoglycemia and dementia in a biracial cohort of older adults with diabetes mellitus. *JAMA Intern Med.* 2013;173(14):1300-1306.

29. Craft S, Claxton A, Baker LD, et al. Effects of regular and long-acting insulin on cognition and Alzheimer’s disease biomarkers: a pilot clinical trial. *J Alzheimers Dis.* 2017;57(4):1325-1334.

30. Craft S, Baker LD, Montine TJ, et al. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. *Arch Neurol.* 2012;69(1):29-38.

31. Lobo RA. Hormone-replacement therapy: current thinking. *Nat Rev Endocrinol.* 2017;13(4):220-231.

32. vTv Therapeutics Announces Topline Results from the First STEADFAST Phase 3 Study Evaluating Azeliragon in People with Mild Alzheimer’s Disease [press release]. Available at: https://www.businesswire.com/news/home/20180409006413/en. Accessed December 2018.

33. vTv Therapeutics Presents Positive Data on the Effect of Azeliragon in Patients with Alzheimer’s and Diabetes at the 11th Clinical Trials on Alzheimer’s Disease (CTAD) Conference [press release]. Available at: https://www.businesswire.com/news/home/20181024005226/en. Accessed December 2018.

34. Claxton A, Baker LD, Hanson A, et al. Long acting intranasal insulin detemir improves cognition for adults with mild cognitive impairment or early-stage Alzheimer’s disease dementia. *J Alzheimers Dis.* 2015;45(4):1269-1270.

35. Reger MA, Watson GS, Frey WH, 2nd, et al. Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype. *Neurobiol Aging.* 2006;27(3):451-458.

36. Craft S, Asthana S, Schellenberg G, et al. Insulin effects on glucose metabolism, memory, and plasma amyloid precursor protein in
Alzheimer’s disease differ according to apolipoprotein-E genotype. *Ann N Y Acad Sci.* 2000; 903:222-228.

79. Malek-Ahmadi M, Beach T, Obradov A, et al. Increased Alzheimer’s disease neuropathology is associated with type 2 diabetes and ApoE epsilon4 carrier status. *Curr Alzheimer Res.* 2013;10(6):654-659.

80. Luchsinger JA, Tang MX, Shea S, Mayeux R. Hyperinsulinemia and risk of Alzheimer disease. *Neurology.* 2004;63(7):1187-1192.

81. Profenno LA, Faraone SV. Diabetes and overweight associate with non-APOE4 genotype in an Alzheimer’s disease population. *Am J Med Genet B Neuropsychiatr Genet.* 2008; 147B(6):822-829.

82. Burns JM, Donnelly JE, Anderson HS, et al. Peripheral insulin and brain structure in early Alzheimer disease. *Neurology.* 2007;69(11):1094-1104.

83. Burns JM, Honea RA, Vidoni ED, Hufles LJ, Brooks WM, Swerdlow RH. Insulin is differentially related to cognitive decline and atrophy in Alzheimer’s disease and aging. *Biochim Biophys Acta.* 2012;1822(3):333-339.

84. De Felice FG, Vieira MN, Bomfim TR, et al. Protection of synapses against Alzheimer’s-linked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers. *Proc Natl Acad Sci U S A.* 2009;106(6):1971-1976.

85. Chen Y, Zhou K, Wang R, et al. Antidiabetic drug metformin (Glucophage®) increases biogenesis of Alzheimer’s amyloid peptides via up-regulating BACE1 transcription. *Proc Natl Acad Sci U S A.* 2009;106(10):3907-3912.

86. Deschaingtre Y, Richard F, Leys D, Pasquier F. Treatment of vascular risk factors is associated with slower decline in Alzheimer disease. *Neurology.* 2009;73(9):674-680.